A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Leukemia, Myeloid, Acute Clinical Trial

Official title:

A Phase 1 Study of Cusatuzumab Plus Azacitidine in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04241549
• Other study ID #: CR108732
• Secondary ID: 74494550AML1002
• Status: Completed
• Phase: Phase 1
• Start date: March 25, 2020
• Est. completion date: July 19, 2021

Study information

• Verified date: August 2023
• Source: OncoVerity, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the recommended Phase 2 dose and evaluate safety profile of cusatuzumab in combination with azacitidine in Japanese participants with treatment naïve acute myeloid leukemia (AML) who are not candidates for intensive treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: July 19, 2021
• Est. primary completion date: July 19, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• For acute myeloid leukemia (AML) participants: AML according to World Health Organization (WHO) 2016 criteria and fulfilling all of the following criteria:(a) more than or equal to (>=) 75 years of age, or younger participants who are not eligible for or not willing to receive an intensive treatment (including stem cell transplantation) with curative intent and (b) previously untreated AML (except: emergency leukapheresis, low dose of cytarabine and/or hydroxyurea during the screening phase to control hyperleukocytosis but must be discontinued at least one day prior to start of cusatuzumab [Part 1] or azacitidine [Part 2]). All trans retinoic acid (ATRA) treatment for presumed acute promyelocytic leukemia (APL) is permitted but must be discontinued at least 1 day prior to the start of cusatuzumab (Part 1) or azacitidine (Part 2)
• For Myelodysplastic Syndrome (MDS) participants (only for Part 2): MDS according to WHO 2016 criteria and fulfilling all of the following criteria: (a) Not eligible for or not willing to receive allogenic stem cell transplantation,(b) very high or high-risk MDS according to Revised International Prognostic Scoring System (IPSS-R) and (c) previously untreated MDS (except: transfusion and/or cytokine therapy including erythropoietin)
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
• Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
• A woman of childbearing potential must have a negative highly sensitive serum (beta human chorionic gonadotropin [beta hCG]) or urine pregnancy at screening

Exclusion Criteria:

• Acute promyelocytic leukemia (APL) with t (15;17), or its molecular equivalent promyelocytic leukemia retinoic acid receptor (PML RAR alpha)
• Leukemic involvement or clinical symptoms of leukemic involvement of the central nervous system
• Known allergies, hypersensitivity, or intolerance to cusatuzumab or azacitidine or its excipients (example, mannitol, an excipient of azacitidine)
• Prior treatment with a hypomethylating agent for treatment of AML or MDS
• A diagnosis of other malignancy that requires concurrent nonsurgical treatment

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Preleukemia

Intervention

Drug:
• Cusatuzumab
Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.
• Azacitidine
Azacitidine at a dose 75 milligram per square meters (mg/m^2) will be administered subcutaneously or intravenously.

Locations

Country	Name	City	State
Japan	Fukushima Medical University Hospital	Fukushima
Japan	Gunmaken Saiseikai Maebashi Hospital	Maebashi
Japan	Osaka City General Hospital	Osaka
Japan	NTT Medical Center Tokyo	Tokyo
Japan	University of Fukui Hospital	Yoshida

Sponsors (3)

Lead Sponsor	Collaborator
OncoVerity, Inc.	argenx, Janssen Pharmaceutical K.K.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1 and Part 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)	Number of participants with AEs and SAEs will be reported.	Up to 3 years
Primary	Part 1 and Part 2: Number of Participants with Dose-Limiting Toxicity (DLTs)	Number of participants with DLTs will be reported.	Up to 42 days
Primary	Part 1 and Part 2: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)	Severity of DLT as assessed by NCI-CTCAE in participants will be reported.	Up to 42 days
Secondary	Part 1 and Part 2: Percentage of Participants with Complete Response (CR)	Percentage of participants with complete response based on response criteria per investigator assessment in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) will be reported.	Up to 9 months
Secondary	Part 1: Objective Response Rate (ORR)	ORR is defined as percentage of participants with CR, CRh and CRi based on response criteria per investigator assessment in participants with AML.	Up to 6 months
Secondary	Part 2: Objective Response Rate (ORR)	ORR is defined as the percentage of participants with CR, partial response (PR) and marrow CR based on response criteria per investigator assessment in participants with MDS.	Up to 9 months
Secondary	Part 2: Percentage of Participants with Hematologic Improvement (HI)	Percentage of participants with hematologic improvement will be reported according to response criteria per investigator assessment in participants with MDS.	Up to 9 months
Secondary	Part 1 and Part 2: Time to Response	Time to response is defined as time from first dose to achieving the first response of CR, CRh, or CRi in participants with AML and CR, PR or marrow CR in participants with MDS..	Up to 3 years
Secondary	Part 1 and Part 2: Duration of Response	Duration of response is defined as time from achieving the first response of CR, CRh, or CRi in participants with AML and CR, PR or marrow CR in participants with MDS to hematologic relapse or death of any cause.	Up to 3 years
Secondary	Part 1 and Part 2: Red Blood Cell (RBC) or Platelets Transfusion Independence	Transfusion independence (RBC or platelets) is defined as a period of at least 56 consecutive days with no transfusion between first dose of study drug and the last dose of study drug +30 days.	Up to 3 years
Secondary	Part 1 and Part 2: Overall Survival (OS)	OS is defined as the time from initial study intervention administration to death from any cause.	Up to 3 years
Secondary	Part 1 and Part 2: Maximum Serum Concentration (Cmax) of Cusatuzumab	Cmax is the maximum observed serum concentration.	Up to 3 years
Secondary	Part 1 and Part 2: Serum Trough Concentration (Ctrough) of Cusatuzumab	Ctrough is the serum concentration immediately prior to the next drug administration.	Up to 3 years